The capacity of the brain for information processing relies on the number and the molecular and functional diversity of neurons, their topographically precise connectivity and their metabolic and signalling interactions with glial cells. The developing nervous system encompasses a range of interacting signalling pathways, which are individually controlled along unique temporal and spatial scales. During brain development, neural progenitor cell proliferation and asymmetric division, and the positioning and molecular diversification of neuronal and glial progenies, are modulated by both cell-autonomous and cell-cell interactions of morphogenetic signals that are crucial to building complex tissues. Among these structurally and functionally diverse signalling domains, bioactive signalling lipids (for example, phospholipids, sphingolipids, glycolipids and prostanoids) are widely recognized as crucial for neuronal and glial differentiation, as well as for synaptic plasticity [1] [2] [3] . Recent work has highlighted similar but unexpectedly diverse roles in the developing nervous system for the endocannabinoid family of small signalling lipids, N-acyl-amines and 2-acyl-glycerols, which typically contain an arachidonoyl moiety 4, 5 . Indeed, evidence suggests that there is a continuum of action by endocannabinoids, overarching the early stages of embryo development and implantation 6 , nervous system development 7 , bioenergetics 8 and intercellular communication 9, 10 in the adult, including adult neurogenesis 11, 12 . More specifically for the nervous system, endocannabinoid signalling seems to be a multimodal communication cassette that is involved in patterning neuronal connections, the synaptic efficacy of which, once they are mature, is often also modulated by endocannabinoids 7 (FIG. 1a) . The widespread nature of endocannabinoid modulation of both excitatory and inhibitory synaptic neurotransmission in the postnatal brain 9 and spinal cord 13 (FIG. 1b) suggests that developmental rules might place these small signalling lipids into a crucial arch of the molecular machinery controlling synaptic neurotransmission.
, which is a mixed endovanilloid and endocannabinoid ligand. 2-AG, AEA and related lipids can stimulate cannabinoid 1 receptors (CB1Rs) and CB2Rs and the nuclear fatty acid receptors peroxisome proliferatoractivated receptor-α (PPARα) and PPARγ (REF. 18 ). 2-AG generally has higher efficacy at CB1R and CB2R, whereas AEA is a low-efficacy agonist that can function as a partial agonist (or even antagonist) in tissues with low receptor reserve or at receptors that are inefficiently coupled to downstream effectors. AEA and 2-AG can stimulate PPARs at high concentrations, although related molecules such as N-oleoylethanolamine do so more potently. Moreover, AEA can engage transient sn-1-diacylglycerol lipase-α (DAGLα). Two isoforms of DAGL, DAGLα and DAGLβ, which probably evolved evolutionarily through gene duplication, are chiefly responsible for 2-AG synthesis.
Tripartite synapse
A concept of synaptic anatomy that includes the presynaptic terminal, postsynaptic specialization and astroglial end-feet that isolate the synaptic cleft as a discrete entity.
receptor potential cation channel subfamily V member 1 (TRPV1) and G protein-coupled receptor 55 (GPR55) 18 . Although gaps persist in our knowledge of endocannabinoid action during formation of the subcortical forebrain, midbrain and spinal cord, the studies highlighted in this section define multiple steps of cortical and cerebellar development modulated by endocannabinoids, which have been elucidated through the use of an impressive range of genetic and cellular tools [19] [20] [21] [22] [23] [24] and evolutionary deductions 25, 26 , as well as experimental models in invertebrates 27 , non-mammalian vertebrates 28, 29 , rodents [30] [31] [32] [33] [34] and human foetal tissues [35] [36] [37] [38] . The evidence for endocannabinoid involvement in fundamental developmental processes comes from the combination of sophisticated mouse genetics 21, 39 , neurophysiology 40 and the study of gene polymorphisms for CB1R, CB2R, α/β-hydrolase domain-containing 12 (ABHD12) and fatty acid amide hydrolase (FAAH) in humans with diseases that are thought to have a developmental origin, such as schizophrenia, bipolar disorder, drug addiction, metabolic disorders and neuro degeneration [41] [42] [43] [44] [45] . These studies support causality between dysregulated endocannabinoid signalling and neuropsychiatric illnesses. Thus, the interdisciplinary nature of this Review provides a translational framework that bridges (at least) two key areas of neuroscience: neurophysiology; and psychiatric and addiction research.
Endocannabinoid signalling at CB1R and CB2R in neural progenitor cells and postmitotic neurons 11, 24, 46 is recognized as the primary molecular substrate for phyto cannabinoids 47 , most prominently for psychoactive Δ 9 -tetrahydrocannabinol (Δ 9 -THC). In this context, and after discussing the multifarious roles of endocannabinoid signalling in the prenatal and perinatal brain, we address endocannabinoid contributions to regulating adult neurogenesis, as cannabis use might affect the continued production of new neurons in adolescents. We examine the molecular mechanisms and the health benefits of exploiting the endocannabinoid system as a druggable target in pathologies that arise from the loss of cell proliferation control, particularly gliomas. Finally, we highlight differential sensitivities of precisely controlled physiological processes versus disease pathomechanisms to help to put the ongoing public debate about the use of Δ 9 -THC during pregnancy and in adolescents into a more realistic context.
Molecular logic of endocannabinoid action
Much of what we know about the molecular organization of endocannabinoid signalling during neuronal development (schematically depicted in FIG. 1a) comes from the comparative analysis of successive developmental stages in rodents 11, 22, 32, 33, 46, 48 (FIG. 2a-d ). Arrangements at mature synapses are such that 2-AG synthesis is postsynaptic 15, 16, 49 with sn-1-diacylglycerol lipase-α (DAGLα) enriched in the 'perisynaptic annulus' (that is, 50-100 nm from the postsynaptic density 50 ), which allows the fast coupling of postsynaptic metabotropic receptor activation to Ca 2+ and phospholipase Cβ-dependent 2-AG synthesis 51 (FIG. 1b) . Diffusing in a retrograde manner across the synapse, endocannabinoids activate presynaptic CB1Rs, typically signalling via G i proteins to inhibit synaptic neurotransmission (FIG. 1b ). 2-AG is then mainly inactivated by presynaptic monoacylglycerol lipase (MAGL) 52 , with a possible contribution from ABHD6 and ABHD12 (REFS 45, 53) , which are partitioned to postsynaptic sites (FIG. 1b) . The situation with AEA is more complex. AEA can be produced postsynaptically to inhibit synaptic transmission in a retrograde manner as in the case of 2-AG 54 . Alternatively, N-arachidonoylethanolamine-selective phospholipase D (NAPE-PLD) may produce AEA presynaptically, which then functions at post synaptic TRPV1 (REFS 55, 56) and is inactivated by postsynaptic FAAH 57 . Notably, and in accordance with the tripartite synapse hypothesis, perisynaptic astrocytes often contain MAGL (FIG. 1b) , thus forming a barrier that may limit 2-AG spread beyond its intended site of action (20-100 µm in a temperature-sensitive manner) 58, 59 . At least four premises should be considered to appreciate the unique modes of endocannabinoid signalling during brain development, and these are discussed in this section. First, in differentiating neural tissues, endocannabinoids can adopt a primarily autocrine (cellautonomous) mechanism of action 19, 48, 60 , in contrast to retrograde signalling by endocannabinoids at adult synapses, which is a paracrine mechanism 9 . If receptor location remains constant, this gives positional differences in the localization of enzymes to influence 2-AG bioavailability. An example is DAGLα, which switches from an axonal to a postsynaptic localization 48, 51 following differentiation of the presynapse and commencement of synaptic neurotransmission 51 . For cell-autonomous endocannabinoid signals to drive neural progenitor cell proliferation, including pathological situations during tumorigenesis (see below), the intracellular transport and partitioning of DAGLα are proximal to the localization of CB1Rs and CB2Rs 46 , which are poised for receptor activation by lateral ligand diffusion in the plasmalemma (FIGS 1,3a) . DAGLα, and to a lesser extent NAPE-PLD, are found in lipid rafts 61 -membrane specializations that allow CB1R accumulation and focus signal transduction by the recruitment of effector kinases 62 . Following neuronal polarization and during directional axonal growth, 2-AG is protected from ligand degradation 48 by a mechanism that increases MAGL protein turnover 63 in motile neurite domains, particularly in the growth cone (FIG. 3a) . High levels of axonal MAGL function to prevent the premature, ectopic activation of CB1Rs (and perhaps CB2Rs 64 ) during axonal transport. Thus, endocannabinoid 'hot spots' exist for focal signalling events. Second, neural progenitor cells, in contrast to differentiated neurons, commonly coexpress CB1Rs and CB2Rs. Pharmacological and histochemical evidence show predominant CB2R expression in the subventricular zone of the cerebral cortex 11 (FIG. 2a) . On the basis of simultaneous expression of CB2R and DAGLα and DAGLβ in neural progenitor cells, it is probable that autocrine endocannabinoid signalling supports asymmetric cell division, cell cycle exit and long-range migration of the ensuing progenies 11, 46, 60 . Following commitment to a neuronal fate, a CB2R-to-CB1R switch occurs 11 : CB1R levels become upregulated at the expense of CB2R levels (FIG. 2b,d ). Although direct experimental evidence for causality is lacking, experimental data from various vertebrate species 28, 29, 65, 66 suggest that early CB1R expression might promote neuronal polarization and the commencement of long-range cell migration. The downregulation of DAGLα and DAGLβ expression that occurs following neuronal specification can be viewed as a pivotal step to increase the reliance of postmitotic neurons on extracellular 2-AG produced by pyramidal cells in the cortical plate 51 , functioning as positional cues (FIG. 2a,c) .Third, as neurogenesis precedes gliogenesis 67 , the spatial spread of endocannabinoids in the foetal brain is less restricted than in the adult brain. Thus, physiologically relevant ligand concentrations could affect, in bulk, cohorts of migrating neurons or axons during pathfinding 63 (FIG. 2a, c ). This suggests that there are wider roles for endocannabinoids in cell-cell interactions than was previously thought. Nevertheless, it remains to be established whether these signalling lipids preferentially modulate contact guidance or indeed are even extracellularly released. Finally, enzymatic inactivation is a rate-limiting step for endocannabinoid signalling in the developing nervous system 48, 68 . Considerable levels of FAAH and MAGL have been shown in cultured neural progenitor cells 19, 20 and radial glia 48, 69, 70 , which generate postmitotic cortical neurons 71, 72 and function as cellular scaffolds for radial migration of neurons 73 . As radial glia produce a checkerboard-like patterned map, converting neural progenitor cell distribution along the ventricular wall into a three-dimensional neuronal protomap in the cortical plate 72 , this cell type is ideally positioned to limit endocannabinoid diffusion (FIG. 2a) . Furthermore, thalamocortical axons accumulate MAGL 33, 48 , which produces corridors for CB1R-containing corticothalamic axons during the corticothalamic-thalamocortical handshake.This MAGL localization can both limit axonal spread in the prospective internal capsule (FIG. 3b) , as well as delineate migratory routes for CB1R-expressing cortical interneurons 65, 74 (FIG. 2a,c) . Overall, the molecular architecture of endocannabinoid signalling networks can modulate cell proliferation, as well as the migration, polarization and synaptogenesis of postmitotic neurons in the cerebral cortex. Neuronal and glial components of developing and mature synapses are shown. The molecular architecture shown here is for a 'stereotypical' synapse that uses endocannabinoid signalling. There are differences in neurotransmitter system-specific and developmentally regulated enzyme and/or receptor expression and function at different types of synapse and at different stages of development. For example, monoacylglycerol lipase (MAGL) is excluded from motile growth cones until synaptogenesis commences 48, 68 . a | At the developing synapse, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) initiate downstream signalling by binding to their target receptors: cannabinoid 1 receptor (CB1R), CB2R, G protein-coupled receptor 55 (GPR55) and transient receptor potential cation channel subfamily V member 1 (TRPV1). Their availability is determined by biosynthesis enzymes (N-acylphosphatidylethanolamine-specific phospholipase D, NAPE-PLD, sn-1-diacylglycerol lipase-α (DAGLα) and DAGLβ
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) and degrading enzymes (fatty acid amide hydrolase (FAAH) and MAGL). It is not yet known whether alternative hydrolysis enzymes (for example, α/β-hydrolase domain-containing 6 (ABHD6) and ABHD12) also play a part at this stage in development. Unlike other endocannabinoid-binding receptors, CB1Rs are preferentially recruited to, and signal within, cholesterol-enriched membrane microdomains termed lipid rafts 62 . b | At the mature synapse, the availability of AEA and 2-AG is controlled by ABHD6 and ABHD12 hydrolases, in addition to FAAH and MAGL, and also by transmembrane (endocannabinoid transmembrane transporter (EMT)) and intracellular (AEA intracellular transporter (AIT)) transport mechanisms 196 (for example, fatty acid-binding proteins 199 , heat shock protein 70 (REF. 197) and FAAH-like AEA transporter 198 ) and storage organelles (adiposomes or lipid droplets) 199 . There is compelling evidence that key receptor and enzyme components of the endocannabinoid system have distinct subcellular distribution, both intracellularly and extracellularly on presynaptic and postsynaptic neurons, microglia and astrocytes. CB2Rs are mainly expressed following brain injury 200 . Question marks indicate as yet unknown roles and compartmentalization of ABHD12. AIT, AEA intracellular transporter; EMT, putative endocannabinoid transmembrane transporter; ER, endoplasmic reticulum; TRKs, tyrosine receptor kinases. 
Corticothalamicthalamocortical handshake
Where corticothalamic and thalamocortical axons with opposite growth trajectories cross one another.
Cannabinoid receptor signalling in foetal brain Although the role of CB1R, CB2R, TRPV1 and GPR55 has been examined in prenatal and/or postnatal neurodevelopment, including cell survival and tumorigenic transformation [75] [76] [77] [78] [79] [80] [81] , a role for endocannabinoid interactions with PPARs remains to be established. Given the predominance of CB1R mRNA and protein expression in the foetal nervous system of rodents 46, 82 and humans 83 , we focus on signal transduction, heteromerization and upstream regulation of CB1R levels and activity.
CB1Rs primarily couple to G i/o proteins and commonly signal by inhibition of adenylyl cyclase and of certain voltage-dependent Ca 2+ channels, as well as by activation of some K + channels (reviewed in REF. 18 ). In stem cells, glial cells and neurons, CB1Rs also activate the phosphatidylinositol 3-kinase (PI3K)-AKT (also known as PKB)-mammalian target of rapamycin (mTOR) pathway along with several mitogen-activated protein kinase (MAPK) pathways (for example, extracellular signal-regulated kinase (ERK), p38, and JUN N-terminal kinase (JNK) 38, 84 ). Although these signalling events have recently been reviewed in detail 69, 85 , important concepts are that PI3K and AKT recruitment contributes to neuronal polarization by promoting neurite outgrowth 86 , mTOR signalling regulates a proneural transcriptional cascade of PAX6 and TBR2 (also known as EOMES) for expansion of the cortical progenitor Nature Reviews | Neuroscience shown. Activation of tyrosine kinase receptors (particularly the fibroblast growth factor receptor (FGFR) and the high-affinity nerve growth factor (NGF) receptor TRKA) and their activity-dependent phosphorylation are thought to induce 2-arachidonoylglycerol (2-AG) production via sequential activation of phospholipase Cγ (PLCγ), which produces diacylglycerol (DAG). DAG is then converted to 2-AG by sn-1-diacylglycerol lipase-α (DAGLα). The dashed arrow in the plasma membrane indicates lateral 2-AG diffusion that can activate CB1Rs in an autocrine manner. Signalling via G proteins recruited to CB1Rs following agonist binding regulates neuronal morphology by, for example, the phosphorylation of JUN N-terminal kinases (JNKs; for example, JNK1) 38 , which triggers the rapid degradation of stathmin 2 to alter cytoskeletal stability. Alternatively, CB1R activation can modulate the activity of RHO-family GTPases, particularly RHOA, to induce growth cone repulsion and collapse 21, 31 . Neurotrophins and 2-AG signalling can coincidently activate phosphatidylinositol 3-kinase (PI3K)-AKT signalling. This, in turn, influences the activity of the transcriptional regulators PAX6 and cyclic AMP response element-binding protein (CREB) and their control of neural progenitor cell proliferation and fate decisions (reviewed in REF. 86 ). Cytoplasmic breast cancer-associated protein 1 (BRCA1; which is activated by PI3K signalling) is one of the candidate E3 ubiquitin ligases controlling monoacylglycerol lipase (MAGL) degradation 68, 86 . b | The left-hand panel shows the spatial segregation of molecular determinants of 2-AG signalling during the corticothalamic-thalamocortical axonal 'handshake'. Corticofugal axons are CB1R positive (stained red), whereas thalamocortical axons are CB1R negative but MAGL positive (stained green) 48 . The right-hand panel shows that corticofugal axons express DAGLs 51 and can use paracrine 2-AG signalling for fasciculation (step 1). In turn, autocrine 2-AG signalling in corticofugal axons might be sufficient to promote their elongation (step 2). This molecular layout is compatible with MAGL-positive thalamocortical axons limiting the spatial spread of 2-AG (step 3; the dashed line indicates 2-AG inactivation), thus controlling the distribution of corticofugal fascicles and confining their growth trajectories to a subpallial corridor. Accordingly, pharmacological inhibition of MAGL activity during corticogenesis disrupts the formation of the corticofugal projection system 201 . c | The subcellular switch of DAGL and MAGL during neuronal polarization and synaptogenesis is shown. In immature neurons, DAGLα is localized to the primary neurite (quiescent axon) and the growth cone, and is probably involved in autocrine signalling. However, once synapses are formed, DAGLα expression is excluded from more proximal parts of the axon and is redistributed to the somatodendritic axis of neurons. By contrast, MAGL becomes enriched at the presynapse, where it probably functions as a 'stop' signal to limit 2-AG-mediated neurite elongation 48 . The precisely timed molecular reconfiguration of 2-AG signalling supports a continuum of endocannabinoid actions during neuronal differentiation, leading up to the retrograde control of synaptic neurotransmission (inset). DAGLα is selectively enriched in the perisynaptic annulus of dendritic spines (pink shading) apposing glutamatergic afferents 49, 202 . cfa, corticofugal axon; ctx, cerebral cortex; f, fimbria; hc, hippocampus; lv, lateral ventricle; PIP 2 , phosphatidylinositol 4,5-bisphosphate; tca, thalamocortical axon; th, thalamus. Figure 
Cytoskeletal instability
The dynamic reorganization of the cytoskeleton by differentially altering the elongation and shortening of the '+' and '-' ends of mictotubules.
cell pool in mice 32, 46, 87 , and JNK1 links CB1R activity to cytoskeletal instability to determine the morphological phenotypes of neurons 38 (FIG. 3a) .
Additional modes of CB1R (and probably CB2R) signalling add to the complexity of endocannabinoid signalling and cell stage-specific influence. These additional modes of signalling include sequestration of G proteins 88 , shifting the balance of signalling between GPCRs that co-exist at the same synapse, or heteromerization with other GPCRs 89 , inducing G protein switching and differential pharmacology 90 . From a developmental standpoint, CB1R interplay with neurotrophin signalling seems to be of particular importance. First, CB1Rs can transactivate certain receptor tyrosine kinases 91 , particularly TRKB in the absence of brain-derived neurotrophic factor (BDNF) 92 by a mechanism involving SRC kinase activation, and can signal via β-arrestins 93 . Second, BDNF can sensitize CB1Rs and induce signal transduction (by ERK and AKT phosphorylation) at otherwise sub-threshold levels of exogenously applied agonists 94 . Third, 2-AG signalling at CB1Rs can function as an essential effector of neurotrophin signalling 68, 95 . This concept (FIG. 3a) was introduced when fibroblast growth factor receptor (FGFR) activation by neural cell adhesion molecules was shown to couple to neurite outgrowth in a CB1R-dependent manner 95 . Mechanistically, FGFR activation induces phospholipase Cγ (PLCγ) activation, which generates arachidonoyl-containing diacylglycerol (DAG) for conversion to 2-AG by DAGLα and DAGLβ and exerts cell-autonomous actions on CB1Rs in motile growth cones. A similar mechanism was more recently described for TRKA (also known as high-affinity nerve growth factor receptor) signalling 68 via the PI3K pathway, leading to increased expression of DAGL, MAGL and CB1R. Notably, increased 2-AG content and focal signalling in growth cones was maintained by the coordinated, nerve growth factor (NGF)-dependent expression of E3 ubiquitin ligases, including breast cancer-associated protein 1 (BRCA1) 68, 86 , to mediate MAGL degradation (FIG. 3a) . As such, both DAGL and CB1R inhibition abolish neurotrophin-induced neurite outgrowth 68, 95, 96 in cerebellar and subcortical neurons, which supports the hypothesis that neurotrophin signalling uses endocannabinoids to regulate neurite extension. Similarly, netrin signalling at its receptor, deleted in colorectal cancer (DCC), is modulated by CB1Rs and CB2Rs 31,64 , which affects netrin-induced growth cone steering decisions and directional axonal growth in the developing visual system. The pathophysiological implications of these interactions are considerable, including disrupted neuronal migration 92 , faulty growth cone turning decisions 21,31,64 and incomplete hemispheric segregation of visual pathways 31 . TRPV1 channels 97 may be located on the plasma membrane or on intracellular membranous compartments such as the endoplasmic reticulum (ER) 98 . In both cases, TRPV1 activation by AEA will increase levels of cytoplasmic Ca 2+ , which thus stimulates diverse Ca 2+ -dependent signalling pathways. Activation of plasma membrane TRPV1 will also tend to depolarize the cell, which may be important not only for differentiation but also to adjust responsiveness to, for example, neurotrophin and netrin signalling through Ca 2+ -dependent cyclic AMP production. Moreover, and in contrast to the usual pro-survival actions of AEA through CB1R, TRPV1 activation by AEA and related lipids can lead to cell death via the ATF3-dependent ER stress pathway 75 . As such, the existence of a signalling axis between AEA-activated TRPV1 controlling 2-AG biosynthesis and biological activity at CB1Rs in the foetal brain, such as in adult striatum 99 , remains to be determined. Therefore, future research might be increasingly directed towards understanding the differential involvement of multireceptor mechanisms in the wiring of neuronal networks by determining how the balance of receptor activities pertains to unwanted changes in neurogenesis, gliogenesis and neuronal differentiation.
Endocannabinoids and neural development
The bioavailability of 2-AG and AEA strikingly diverges as the embryo develops 100, 101 . AEA predominates in the blastocyst and early embryonic stages, and is required for embryo implantation and the maintenance of pregnancy 6 . By contrast, 2-AG levels gradually increase as tissue differentiation progresses, including in the nervous system, in which DAGLα and DAGLβ expression in developing axonal tracts during the mid-and late-gestational periods exceeds that in the later stages of development 48, 51 (FIG. 2a) .
A series of elegant experiments from the laboratory of Ismael Galve-Roperh combined mouse genetics and in vitro models to show that endocannabinoids control the size of the neural progenitor cell pool in the developing forebrain and are particularly important for adopting neuronal versus astroglial cell fate in the hippocampus and cerebral cortex 19, 20, 87, 102 . These studies revealed that neural progenitor cells express CB2Rs, along with CB1Rs, and that CB2R activation by non-psychoactive cannabinoids and endocannabinoids and downstream PI3K-AKTmTOR complex 1 (mTORC1) signalling modulates the expansion of the neural progenitor cell pool in vitro and in vivo 102, 103 . Although there are considerable gaps in our current knowledge about the integration of endocannabinoid signals in neurogenic niches at the receptor level and the specific contributions of 2-AG, AEA and other endocannabinoids, the consensus view is that neurogenic fate decisions coincide with a CB2R-to-CB1R switch in postmitotic neurons 11 . This could explain the predominance of CB1R expression (FIG. 2b) (FIG. 2d) .
The event of receptor switching parallels the downregulation of DAGL expression in postmitotic neurons 60 , which allows the cessation of proliferation-promoting autocrine 2-AG signalling (FIG. 2a) . Rather, reliance of the differentiating progeny on paracrine (target-derived) positional endocannabinoid signals increases. Such a mechanism is probably relevant for radially migrating pyramidal cells to migrate from the cortical progenitor cell niche towards the prospective cortical plate along a vertically decreasing 2-AG gradient. This also implies that CB1Rs transduce repulsive signals to maintain the directionality of neuronal migration. A similar mechanism
Fasciculation
The process by which developing axons follow a primary pioneer axon, thus maintaining strict directionality towards a distal target. might operate in some, if not all, GABA interneurons 65 migrating tangentially in the superficial and deep migratory streams from subcortical ganglionic eminences towards endocannabinoid-rich cortical domains 48 (FIG. 2a,c) . We propose that GABA interneurons use 2-AG signals to avoid the DAGLα-and DAGLβ-rich cortical plate (note that pyramidal cells populate the cortical plate days earlier than interneurons 104 ) and migrate in endocannabinoid-sparse cortical corridors instead. This hypothesis also takes into account that focal endocannabinoid gradients are probably present (see below) to control the direction of cell migration 92 , and integrates radial glia as a cell contingent that terminates long-range migration by endocannabinoid inactivation 46 . In addition to its probable contribution to shaping the path of migrating GABA interneurons, DAGL expression in pyramidal cells can also subserve the growth of corticofugal axons. This is supported by the axonal localization of CB1Rs, which suggests that autocrine and paracrine modes of action can promote neurite elongation 48 , fasciculation and directionality 29, 31 (FIG. 3b) . Recent experimental -particularly in vitro -evidence suggests that CB1Rs, CB2Rs 64 , TRPV1 and GPR55 couple to neurite growth by modulating lateralized Ca 2+ signalling 105 in axonal growth cones, which represent a direct link to cytoskeletal reorganization following exogenous ligand exposure in various cell systems 80, 81, [106] [107] [108] [109] [110] . In this section, we focus on CB1R-mediated axonal growth, the physiological importance of which is supported by genetic and pharmacological analyses (FIG.4; TABLE 1) . Initially, CB1Rs, even though they are signalling competent 111 , were thought to be expressed at 'atypical locations' in foetal brains (that is, in the white matter instead of at synaptic sites) 100, 111 . In subsequent studies, the selective exposure of CB1Rs on the axonal surface was shown 23, 112 and their activation was shown to induce repulsive growth cone turning and eventual collapse, at least in vitro 21, 31 . The molecular mechanism of CB1R-mediated cytoskeletal instability in growth cones is thought to involve RHO-family GTPases
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, RAS and PI3K-AKT-β-catenin signalling 95, 113 (FIG. 3a) . In single-cell systems 21, 31 , CB1R-mediated repulsive growth cone turning involves neurite extension, whereas growth cone collapse is followed by neurite retraction, growth cone reinstatement and renewed extension and motility along alternative paths. The highly dynamic steering behaviours of advancing growth cones in the presence of repulsive cues might be translated to the complex three-dimensional structure of the developing cerebrum, in which precisely configured 2-AG sources are organized in corridor-like patterns such that repeated cycles of repulsion-alternative pathfinding responses, which result in net neurite elongation, propel CB1R + axons along their growth trajectory. These considerations, together with CB1R expression being restricted to developing neurons destined to the cerebral cortex 46, 65 , suggest that endocannabinoid signalling is particularly important for cortical development and that the targeting of long-range axons leaving the cerebral cortex (termed corticofugal axons) might switch from endocannabinoiddependent to non-endocannabinoid-mediated forms of axon guidance after passing the pallio-subpallial boundary. The fact that thalamocortical axons express MAGL (FIG 3b) raises the possibility that, during the process of the thalamocortical-corticothalamic handshake when axons along opposite paths use in trans signalling to maintain directional motility in the internal capsule, MAGLmediated 2-AG inactivation can change axonal growth rate, modulate directionality and determine the size of axon fascicles by adjusting the number of axons that navigate together. Although data using JZL184, which is a MAGL inhibitor, in cell culture systems suggests a role for MAGL in growth rate control 48 , in vivo support for this hypothesis is not yet available. Moreover, and even though the extracellular matrix proteins glypican (a heparan sulphate proteoglycan) and neurocan (a chondroitin sulphate proteoglycan) have been proposed to be downstream targets of CB1Rs during axonal growth 38 , mechanistic insights in endocannabinoid-mediated axon 
Functional antagonist
A drug that is pharmacologically classified as an agonist; it induces a phenotype similar to that provoked by an antagonist, often by downregulation of signalling.
fasciculation remain elusive. Nevertheless, a key observation is that, once synaptic wiring occurs, DAGL 51 and MAGL 48 become redistributed in neurons (FIG. 3c) , with DAGL exclusively present in the somatodendritic domain of neurons and MAGL assuming a presynaptic localization. Although we do not yet know the molecular filters that exclude these enzymes from particular subcellular compartments, this molecular reorganization is clearly crucial for the retrograde control of synaptic neurotransmission to become operationa l in the juvenile brain [114] [115] [116] .
Endocannabinoid contributions to gliogenesis
Although most studies have focused on the role of endocannabinoids in neuronal differentiation, essential data suggest that these signalling lipids are also important in regulating astrogliogenesis, oligodendrogliogenesis and differentiation 19, [117] [118] [119] [120] [121] . Indeed, CB1R activation promotes astroglial differentiation of mouse neural progenitor cells in culture 19, 122, 123 and in the postnatal and adult mouse hippocampus in vivo 124 . Furthermore, CB1R stimulation enhances the survival of rat astrocytes in culture and in the adult rat hippocampus in vivo, probably by a focal signalling mechanism (that is, cultured astroglia express CB1R, CB2R, MAGL and FAAH, which raises the possibility of both autocrine and paracrine signalling 19, 20 ) and reliance on the PI3K-AKT pathway (FIG. 3a) .
The enzymes responsible for 2-AG synthesis and degradation were found in oligodendrocytes 118, 119 , which produce high levels of 2-AG. As oligodendrocytes also express CB1R and CB2R and respond to MAGL inhibition (by JZL184) by rapid morphological differentiation, particularly the formation of highly ramified processes 118 , it is probable that autocrine 2-AG signalling dominates in driving oligodendroglial maturation. Moreover, agonist activation of both CB1Rs and CB2Rs enhances the survival of oligodendrocyte progenitor cells in culture. These effects are induced by the CB1R-and CB2R-mediated activation of the ERK 119 and PI3K-AKT signalling pathways in vitro 118, 125 . These data were corroborated by studies showing that CB1R and CB2R activation also promote oligodendrogenesis in the subventricular zone of the postnatal rodent brain in vivo 117 , particularly following hypoxic-ischaemic damage in neonatal 126 and adult animals, and following viral encephalitis-induced disease 127 . Although the above observations seem compelling, some investigators have been unable to reproduce these findings, at least when attempting to differentiate mouse neural progenitor cells to generate astroglia or oligodendroglia in vitro 128, 129 . Nonetheless, the recent finding that haemopressin, which is a putative endogenous CB1R inverse agonist, might increase oligodendrogial differentiation of neural progenitor cells isolated from the subventricular zone of neonatal mice 130 suggests that spatially restricted, cell stage-specific endocannabinoid signals could differentially affect the proliferative capacity of neural progenitor cells and could typify the cellular identity of ensuing progenies.
Neurogenesis precedes gliogenesis during brain development 67 . Therefore, we propose that endocannabinoid signalling can be relevant to gliogenesis and differentiation in both autocrine and paracrine contexts. Although autocrine signalling might function in glial progenitor cells to expand available cell pools in gliogenic niches of the brain, paracrine signalling, with DAGL-containing axons serving as the cellular sources of 2-AG, can promote the recruitment of astroglia and oligodendrocytes to specific neuronal foci for metabolic purposes or to myelinate long-range axons to increase their conductance velocity.
Cannabis exposure during pregnancy Developmental neurobiology commonly probes the relevance of any signalling system to brain development by a combination of genetic (knockout) models and pharmacological tools. The >400 bioactive components in Cannabis spp. 47 make the use of pharmacological approaches particularly important in relation to endocannabinoid signalling. In this section, we summarize data from knockout models, from antagonism of CB1Rs and from modulating endocannabinoid metabolism.
Genetic models. The lack of lethality or an otherwise robust nervous system phenotype in constitutive CNR1-knockout mice 131 prompted initial scepticism about endocannabinoids having a mandatory neurodevelopmental role. The first wave of conditional knockout models 21, 32, 46 and detailed morphological analyses 21,32,68 have begun to change this view (FIG. 4; TABLE 1 ) and confirmed that cannabinoid receptors and metabolic enzymes have a particularly robust capacity for compensation and adaptation. These findings also suggest that pharmacological challenges might similarly provoke unwanted developmental complications.
CB1R modulation. Accordingly, a bolus injection of SR414716, which is a CB1R antagonist, into the lateral ventricle of mouse fetuses (at embryonic day 14) 46 recapitulated the arrest of neuroblast migration 24 from the subventricular zone, the ipsilateral cortical delamination and the growth defects of corticofugal axons that are seen in mice lacking CB1R in pyramidal cells 46 (FIG. 4) . Moreover, perinatal injections of AM251, which is another CB1R antagonist, altered the wiring diagram of the barrel cortex by mistargeted axons, thus modifying the whisker map and compromising somatosensory information processing 30 . Similarly, injection of pregnant dams with WIN55,2122, which is a potent and efficacious agonist at both CB1R and CB2R, dysregulated TBR1 and TBR2 expression 132 . This treatment also augmented both radial and tangential neuronal migration in the cerebral cortex with a particular increase in the number of Cajal-Retzius cells in the cortical marginal zone 132 , which could cause the altered glutamate neurotransmission 133 and impaired postnatal learning and memory encoding 134, 135 .
Manipulating endocannabinoid metabolism.
Chronic MAGL inhibition by JZL184, which produces multifold increases in embryonic 2-AG levels, modifies the development of the cortical circuitry by acting as a functional antagonist, with long-lasting consequences for CB1R
Psychoactive component
The molecular component of a plant extract that can provoke acute changes in perception of behaviour.
(and perhaps CB2R) availability and signal competence 68, 136 . Although in vivo confirmation is lacking, on the basis of the dependence of neuronal differentiation on precisely timed 2-AG signalling and of the axonal mistargeting phenotype in DAGLA −/− brains in vivo 63 , we predict that pharmacological inhibition of DAGLs will be detrimental to nervous system development.
Endocannabinoid signalling is a wide-ranging neural cell communication system with many molecular nodes that allow alternative metabolic checkpoints to tightly control endocannabinoid concentrations ('homeostatic balance') and to facilitate broad interactions with coexistent signalling cassettes (see interactions with neurotrophins and netrins above). Thus, it can be postulated that, instead of provoking a gross neurodevelopmental phenotype ('direct hit'), pharmacological or genetic manipulation of select molecular constituents in endocannabinoid signalling networks will induce subtle changes in many neurons and synapses, which only manifest as a disease following exposure to a secondary stressor ('double hit'). This concept is compatible with recent studies showing that prenatal or perinatal administration (from embryonic day 10 to postnatal day 7) of URB597, which is a FAAH inhibitor 137 , or following GPR55 deletion 138 , does not markedly affect neurogenesis or axonal development (TABLE 1) . However, both strategies induced long-lasting behavioural deficits, particularly depression-like symptoms and memory impairment, which last into adulthood of the affected offspring. The lack of a clear anatomical phenotype in these models might be explained by moderate GPR55 mRNA expression relative to CNR1 mRNA levels in the brain 138 (which would reduce the effect of these molecular targets) and/ or the 1,000-fold lower levels of AEA than 2-AG in the developing brain 48, 101 , (which would probably trigger functional substitutions by other cannabinoid-sensing receptors and 2-AG). Nevertheless, the behavioural deficits that have been observed are in agreement with the outcome of longitudinal human studies in children who present compulsive and depressive behaviours and deficits in recall and visual memory when they have been prenatally exposed to cannabis 139, 140 .
Transgenerational cannabis effects.
Research of the effects of cannabis on brain development has so far only focused on the analysis of the effect of Δ 9 -THC 34,38, 141, 142 , which is the major psychoactive component. Pioneering studies from the Hurd laboratory have shown increased heroin seeking in offspring prenatally exposed to THC 142, 143 , transgenerational imprinting via epigenetic mechanisms through coincidently enhanced transcriptional repression and reduced transcriptional activation 34 , as well as misplacement of CB1R + hippocampal interneurons in neonatal offspring 92 . The neuronal basis for THC-induced drug-seeking behaviours in the offspring might be due to the altered neuropeptide (dynorphin and enkephalin) expression in mesocorticolimbic reward circuits 144 and the erroneous synaptic wiring of glutamatergic cortical neurons 38 . Modifications to glutamatergic axons were shown to originate during neuronal development and to be due to the CB1R-dependent degradation of brain-specific stathmin 2 (also known as SCG10), which determines microtubule elongation by sequestering tubulin dimers in a ternary T2S complex 145 . The loss of stathmin 2 thus compromises cytoskeletal instability in a molecular mechanism involving the phosphorylation and activation of JNKs, particularly JNK1, which phosphorylate stathmin 2 targeting it for proteasomal degradation 146 (FIG. 3a) . As reduced cytoskeletal instability leads to erroneous neuronal morphologies, particularly neurite outgrowth, the Δ 9 -THC-induced loss of SCG10 compromised corticofugal development. Δ 9 -THC-induced wiring deficits seemed to be permanent, as adult offspring showed synaptic rearrangements, particularly CB1R localization, and reduced long-term plasticity in the hippocampus 38 . Pharmacological manipulation of the endocannabinoid system is also detrimental in neonates and during adolescence. In a provocative series of experiments, Esther Fride and her colleagues suggested that a single injection of SR141716 in newborn mice compromises suckling behaviours so severely that it leads to the death of the offspring 147 . Similarly, prolonged Δ 9 -THC administration in neonates induced learning impairments that lasted into adulthood 148 . For the adolescent period (that is, postnatal days 28-45 in mice), Δ 9 -THC administration impairs social behaviour and cognition, with concomitant alterations in neurochemical indices of both glutamatergic and GABAergic neurotransmission 149, 150 (for example, vesicular transporters and postsynaptic and SNAP receptor (SNARE) complex components). Although most of these data only allow circumstantial conclusions to be made on the basis of cross-correlation s, it is tempting to speculate that pharmacological man ipulation of endocannabinoid signalling during crucial periods of synaptogenesis and/ or postnatal pruning might precipitate or predispose an individual to neuropsychiatric disease-like phenotypes. Our hypothesis is in accord with clinicopathological data showing: signalling-competent CB1Rs in major axonal trajectories in human foetal brains 111 ; disrupted endocannabinoid signalling (particularly CB1R levels) and molecular differentiation of CB1R + GABA interneurons in patients with schizophrenia 151, 152 ; and deficient endocannabinoid signalling in rodent models of autism (neuroligin knockout s 40 ); and deletion of the fragile X gene 153 .
Endocannabinoids in restorative neurobiology
We live in an exciting time for restorative neuroscience, in which key findings in developmental biology are being translated to combat devastating human neurological conditions. In this section, we focus on emerging evidence that endocannabinoids regulate the proliferation of neural stem cells in the adult brain with the hope that persistent neurogenesis might be harnessed for brain repair 154 . In the adult rodent brain, there are neural stem cell niches in the hippocampus and in the subventricular zone of the lateral ventricle, and these generate new neurons that can integrate into mature synaptic circuits to facilitate specialized forms of learning and memory 155 . In the hippocampus, the generation and the differentiation of new neurons is a fairly local event within the dentate gyrus 155 . In the subventricular zone, neural stem cells generally differentiate into migratory neuroblasts that travel a considerable distance along the rostral migratory stream (RMS) to populate the olfactory bulb with new neurons 156 . In humans, a robust RMS is a transient structure that is only obvious for a few months after birth 157 . Nonetheless, proliferative neural stem cells can still be identified in the subventricular zone of aged patients who have suffered a stroke, with new neurons appearing in the adjacent striatum throughout life 158 . Interestingly, subventricular zone neuroblasts can be recruited to sites of brain injury where they might provide trophic support to help preserve function 159 , and recent evidence suggests that neural stem cells and progenitor cells resident in the subventricular zone might also provide 'local' trophic support to neurons residing in the proximal striatum 160 . Epidermal growth factor (EGF) and FGFR signalling have central roles in driving adult neurogenesis 161 , with their respective ligands operating alongside inhibitory factors such as growth and differentiation factor 11 (GDF11) 162, 163 to maintain the balance between neural stem cell quiescence and proliferation 164 . This leaves the cells poised to respond in a positive or a negative manner to other cues, some of which seem to be derived from local microglia 165, 166 . Genetic deletion of cannabinoid receptors, or fairly short-term treatment with CB1R-and CB2R-selective antagonists, suppresses neural stem cell proliferation in the hippocampus and subventricular zone 12, 103 (TABLE 2) . By contrast, activation of cannabinoid receptors with synthetic agonists and/or by increasing the level of endocannabinoids by genetic deletion or pharmacological inhibition of FAAH, stimulates neural stem cell proliferation in both niches 11, 12, 20, 103 . Unexpectedly, stimulating endocannabinoid signalling has more marked effects in ). This wide range of tools 11, 15, 19, 20, 103, 207 has been used to uncover that DAGL-dependent endocannabinoid signalling regulates neural stem cell proliferation in both the dentate gyrus of the hippocampus and the subventricular zone or rostral migratory stream in rodents, with specific effects on neuroblast migration 24 , and that such signalling regulates the appearance of new neurons in the olfactory bulb.
Ceramide
A molecule that consists of sphingosine and a fatty acyl chain; it is therefore one of the structurally simplest forms of sphingolipids.
older animals, which suggests that the natural agerelated decline in neurogenesis might partly reflect a 'run-down' in endocannabinoid tone. In this context, whereas treatment of 6 week-old mice with CB2R agonists increases subventricular neural progenitor cell proliferation by 20-30%, the same treatments results in a 300-400% increase in 6 month-old mice, with an associated threefold increase in the number of new neurons appearing in the olfactory bulb 2 weeks later 11 . 2-AG seems to be the main endocannabinoid that drives adult neurogenesis as there is a 50% reduction in neural stem cell proliferation in the hippocampus and subventricular zone of young adult mice when DAGLα and/or DAGLβ are knocked out 15 . Even greater effects (70-80% loss) are seen in the subventricular zone following acute pharmacological inhibition of these enzymes 11 (TABLE 2) . Neural stem cells express both DAGLs as well as CB1R and CB2R 11 , which suggests that there is an autocrine signalling pathway. However, it is also possible that 2-AG exerts paracrine effects on neighbouring cells, with this type of 'short-range' signalling recently shown to be capable of regulating axonal guidance 63 . In addition to promoting stem cell proliferation, DAGL-dependent activation of both CB1R and CB2R promotes the migration of neuroblasts along the RMS towards the olfactory bulb, again via an autocrine signalling mechanism 24 . As such, endocannabinoid tone stabilizes the leading process on migratory neuroblasts, perhaps allowing them to better read and/or respond to spatial guidance cues within the RMS. The question remains as to how endocannabinoid tone arises and how it is maintained in neural stem cells and migratory neuroblasts. There are many candidate mechanisms as a wide range of growth factors have been implicated in neurogenesis, including FGF2, and have the potential to directly and focally stimulate DAGL-dependent endocannabinoid signalling 95 . Interestingly, recent progress in understanding the key downstream effectors that mediate endocannabinoid signalling has implicated mTORC1 rather than PI3K or ERK 102 ; biochemical and transcriptional experiments suggest that PI3K activity is mainly regulated by the EGF receptor, whereas the EGF and FGF receptors synergistically regulate the ERK pathway 167 . In summary, adult neurogenesis can be considered as a form of structural or cellular plasticity operating within the developed brain; it is highly dynamic with correlative changes seen following injury, in depression and in various neurodegenerative and inflammatory disease states 168 . A considerable body of evidence now supports a key role for endocannabinoid signalling in the regulation of neural stem cell proliferation and the lineage commitment and migration of their progeny. Stimulation of neurogenesis in the adult brain is beneficial, for example, in depression 169 , but substantial benefits in the aged, injured and/or diseased brain remain to be shown. Nonetheless, FAAH inhibitors might be useful drugs for this purpose given the marked effects they have on neurogenesis in older mice 11, 22 and the fact that they have been developed for use in humans, albeit for other conditions 170 .
Cannabinoid receptors in glioma therapy
It is widely thought that the optimal strategy for cancer treatment would involve targeted therapies capable of providing the most efficacious and selective treatment for each individual tumour patient ('personalized therapy'). Glioblastoma multiforme (grade IV astrocytoma) is one of the most malignant forms of human cancer with very short survival times following diagnosis. The recent finding that a small molecule that selectively affects membrane turnover in human glioma cells was efficacious in a preclinical glioma model 171 reinforces the concept that the maintenance of lipid mass in dividing tumour cells is crucial for their continued growth. Moreover, it is known that cannabinoids inhibit tumour growth in animal models of glioma through a mechanism involving inhibition of PI3K-AKT-mTORC1 signalling, which induces apoptosis of tumour cells without affecting their non-transformed counterparts 172 (FIG . 5) . Additional mechanisms, such as inhibition of angiogenesis 173 and invasion 174, 175 , can contribute to the CB1R-and CB2R-induced impairment of glioma growth in mouse models. Moreover, in mice bearing gliomas, cannabinoids potentiate the antitumour efficacy of temozolomide, which is the benchmark agent for the clinical management of gliomas, in a synergistic manner and without overt toxicity 176 . In a pilot Phase I clinical study, intracranial Δ 9 -THC administration to nine patients with actively growing recurrent glioblastoma multiforme was safe and could be achieved without substantial unwanted effects 177 . Importantly, radiological monitoring and analyses of tumour specimens supported the antitumour action of cannabinoids in those cancer patients 172, 177 . Notably, endocannabinoid-sensing receptors (especially CB2R and TRPV1) are upregulated in human glioma tissue compared with normal brain tissue, and their expression positively correlates with tumour grading 75, 178 . The differential receptor expression patterns thus allow potential endocannabinoid drug targets to induce glioma cell death. These findings provide 'proof-of-concept' that endocannabinoid-based medicines can improve the clinical efficacy of classical cytotoxic drugs in patients with glioma. In line with this, a Phase I/II trial for a combination therapy with cannabinoids and temozolomide is currently ongoing (ClinicalTrials.gov identifier: NCT01812603).
The mechanism of action seems to involve ER stress, which is a common theme in cannabinoid-and endocannabinoid-triggered glioma cell death (FIG. 5) . ER stress is activated in response to ER-damaging stimuli and aims to lessen the protein load on the ER by coordinating a temporal shutdown of protein translation and a complex programme of gene transcription to increase the protein-folding capacity of the ER. If this transcriptional programme fails to re-establish ER homeostasis, persistent ER stress will induce cell death. Cannabinoid-induced apoptotic death of glioma cells was shown to stimulate the CB1R and CB2R-dependent de novo synthesis of ceramide. This sphingolipid accumulates in the ER, thereby inducing ER stress through the phosphorylation and inhibition of eukaryotic initiation factor 2α (EIF2α) and the downstream activation of ER stress-related transcription factors such as p8, activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP; also known as DDIT3) 179 . In parallel, fatty acyl ethanolamides (such as AEA) activate TRPV1 receptors located on the ER of glioma cells, inducing Ca 2+ release into the cytoplasm; this probably occurs together with ceramide accumulation to deplete ER Ca 2+ stores and to induce the phosphorylation and inhibition of EIF2α and the upregulation of transcription factors such as ATF3 and ATF4 (REF. 75) (FIG. 5) . These two branches of cannabinoid-and endocannabinoi d-mediated ER stress trigger glioma cell death. In the fatty acyl ethanolamideinduced activation of TRPV1 receptors, cannabinoid receptor-mediated ER stress upregulates the expression of the pseudokinase tribbles homologue 3 (TRIB3), which interacts with and inhibits the pro-survival kinase AKT, thereby leading to the inhibition of mTORC1 and the subsequent stimulation of autophagy-mediated apoptotic cell death 180 . The molecular targets downstream of ATF3 in the TRPV1-mediated ER stress response remain elusive. Incidentally, cannabinoids and endocannabinoids can engage additional ER stress-related mechanisms to trigger neuronal death. As such, AEA induces apoptosis of human neuroblastoma cells through a CB1R-dependent pathway via p38, ERK1, ERK and GRP78 (also known as BiP), which is an ER stress sensor that triggers activation of p53 and p53 upregulated modulator of apoptosis (PUMA; also known as BBC3) 181 .
The widely reported induction of glioma cell death by cannabinoid receptor stimulation is in contrast with the well-known proliferative and pro-survival activity of cannabinoid receptors on neural progenitor cells, neurons and glial cells. In fact, cannabinoid receptors distinctly regulate signal transduction pathways in tumour and non-tumour cells (FIG. 5) . The molecular basis of this 'yin-yang' behaviour is incompletely understood. Nevertheless, the possibility that it relies on different patterns of CB1R and CB2R expression and/or precoupling to effectors seems unlikely for several reasons: glioma cell lines that are resistant to cannabinoid-induced apoptosis express similar amounts of CB1R and/or CB2R compared with cannabinoid-sensitive lines; pharmacological studies using cannabinoid receptor subtype-selective antagonists support that either CB1R or CB2R can induce apoptosis in cannabinoid-sensitive glioma cells 182, 183 ; and the shortterm (minute-range) coupling of CB1R and CB2R to key cell signalling pathways, such as the ERK and AKT pathways, is similar in glioma cell lines that are sensitive or resistant to cannabinoid-induced apoptosis 173, 184 , as well as in primary astroglia 125 or oligodendroglia 120 . Taken together, this evidence suggests that mechanisms other than changes in the expression or intrinsic functionality of cannabinoid receptors might account for the differences in cannabinoid sensitivity of glioma cells. Indeed, a series of studies indicates that this 'yin-yang' behaviour could result from the differential capacity of tumour Receptor tyrosine kinases that have been transactivated (by phosphorylation) might amplify cannabinoid receptor-mediated signalling by also using PI3K and RAS as molecular effectors. Activated AKT can elicit cell growth and survival effects (that is, it is mitogenic) either by inhibiting glycogen synthase kinase 3β (GSK3β) and activating β-catenin 205 or by activating mTORC1, which leads to p27 inhibition 102 as well as PAX6 phosphorylation 86 and upregulation of PAX6 expression 87 . b | In glioma cells, eCBs trigger endoplasmic reticulum (ER) stress by engaging (at least) two mechanisms: binding of eCBs to cannabinoid receptors stimulates de novo synthesis of ceramide in the ER via G i -dependent and perhaps also via G i -independent mechanisms 179, 180 ; and binding of eCBs to transient receptor potential cation channel subfamily V member 1 (TRPV1) receptors on the ER mediates Ca 2+ release from this organelle to the cytoplasm and, conceivably, depletes ER Ca 2+ stores 75 . Ceramide accumulation and Ca 2+ depletion in the ER converge at the phosphorylation (that is, inhibition) of eukaryotic initiation factor 2α (EIF2α) and the induction of activating transcription factor 4 (ATF4), which, in turn, triggers cell death by two signalling cascades: upregulation of tribbles homologue 3 (TRIB3) expression, which leads to the inhibition of the AKT-mTORC1 axis 180 ; and upregulation of ATF3 expression 75 . Nature Reviews | Neuroscience NGF CB 1 173, 181 .
Conclusions
In this Review, we discuss available experimental and translational evidence 185 implicating endocannabinoid signalling in brain development, from neural stem cell survival and proliferation, cell fate decisions and the motility and differentiation of ensuing neuronal and glial progenies. We highlight multiple niches at which developmental endocannabinoid signalling, encompassing the foetal-to-young adult periods, is of importance, including recreational cannabis use during pregnancy and in adolescence affecting structural and functional brain plasticity 185 , adult neurogenesis in which endocannabinoids might be exploited to promote the colonization of areas of neuronal loss and the molecular pathogenesis of gliomas, in which ceramide-induced ER stress is identified as a promising therapeutic target. Despite great progress over the past decades, information is limited as to the involvement of endocannabinoids in the maintenance of neuron-glia interplay, particularly the recruitment of astroglia for metabolic control and oligodendroglia for ensheathing of axons. These areas of research are warranted, as functional CB1Rs are probably expressed by (adult) astroglia 186 , neuron-derived endocannabinoids can induce Ca 2+ signalling and glutamate release from astrocytes 187 and CB1Rs are assumed to be expressed on mitochondria 8 . Although the expression of CB1Rs on mitochondria is controversial 188 , future studies aimed at defining sequential endocannabinoid signal recruitment along distinct timescales to foci of neuronal and glial differentiation will undoubtedly provide fundamental insights into the contribution of signalling lipids to shaping the nervous system. These studies will facilitate the molecular analysis of neuropsychiatric diseases that have presumed developmental origins and in which modifications to endocannabinoid signalling have been observed (including autism 40 , schizophrenia 151, 189, 190 , bipolar disorder 41, 191 and depression 151 ). Attempts to disentangle complex genetic traits and epigenetic mechanisms must rely, at least partly, on modern molecular and cellular tools, to reconcile existing controversies in cannabinoid pharmacology. Thus, advances in our understanding of endocannabinoid actions in subpallial, midbrain and spinal networks is expected and will facilitate the exploitation of axonal responsiveness and glial scaffolding for therapeutic purposes. Further analysis using combinatorial platforms is ultimately warranted to define the importance of endocannabinoid signals among coexisting morphogenetic pathways and to define how they are influenced by metabolic processes. Thus, we await the emergence of consensus views on how targeting the cannabinoid system can be used to alleviate the adverse effects of maternal drug abuse, obesity, diabetes and cardiovascular diseases 192 , which are commonly associated with altered circulating endocannabinoid levels 193 
